
Sign up to save your podcasts
Or


What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss their case — entitled “Intermountain Healthcare: Pursuing Precision Medicine” — and its connections to their work with the Kraft Precision Medicine Accelerator.
By HBR Presents / Brian Kenny4.5
190190 ratings
What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss their case — entitled “Intermountain Healthcare: Pursuing Precision Medicine” — and its connections to their work with the Kraft Precision Medicine Accelerator.

385 Listeners

1,468 Listeners

106 Listeners

152 Listeners

1,102 Listeners

3,988 Listeners

1,381 Listeners

742 Listeners

107 Listeners

175 Listeners

42 Listeners

828 Listeners

676 Listeners

221 Listeners

81 Listeners

170 Listeners

82 Listeners